304 Capecitabine plus irinotecan (XELIRI) in first line metastatic colorectal cancer (MCRC): update on a phase II trial

Authors :: S. G. Eckhardt
W. Miller
F.-C. Lee
G. R. Justice
E. Lin
M. Javie
D. Diamandidis
Y.Z. Patt
J. Leibmann
W. Keiser
Source :: European Journal of Cancer Supplements. 1:S93
Publication Year :: 2003
Publisher :: Elsevier BV, 2003.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
XELIRI
business.industry
Colorectal cancer
First line
medicine.disease
Irinotecan
Capecitabine
Internal medicine
Medicine
business
medicine.drug

Tools